Table 3.
Antimicrobial susceptibility of imipenem-non-susceptible A. baumannii and P. aeruginosa from the TSAR programme, 2018
| Antibiotics |
A. baumannii (n = 136) |
P. aeruginosa (n = 81) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R (%) | I (%) | S (%) | MIC50 (mg/L) | MIC90 (mg/L) | MIC range (mg/L) | R (%) | I (%) | S (%) | MIC50 (mg/L) | MIC90 (mg/L) | MIC range (mg/L) | |
| Ampicillin/ sulbactam | 86.8 | 11.8 | 1.5 | 64 | >64 | ≤4 to >64 | Intrinsic resistance | |||||
| Cefepime | 97.1 | 1.5 | 1.5 | >32 | >32 | 8 to >32 | 28.4 | 25.9 | 45.7 | 16 | 32 | 1 to >32 |
| Cefepime/ zidebactam | 38.2 | 53.7 | 8.1 | 16 | 32 | 8 to >32 | 0 | 8.6 | 91.4 | 4 | 8 | 0.5–16 |
| Cefotaxime | 96.3 | 3.7 | 0 | >32 | >32 | 16 to >32 | Intrinsic resistance | |||||
| Ceftazidime | 97.1 | 0.7 | 2.2 | >32 | >32 | 4 to >32 | 44.4 | 12.3 | 43.2 | 16 | >32 | 1 to >32 |
| Ceftazidime/ avibactam | 98.5 | 0 | 1.5 | >32 | >32 | 8 to >32 | 18.5 | 0 | 81.5 | 4 | 32 | 1 to >32 |
| Imipenem | 99.3 | 0.7 | 0 | >16 | >16 | 4 to >16 | 70.4 | 29.6 | 0 | 16 | >16 | 4 to >16 |
| Imipenem/ relebactam | 99.3 | 0 | 0.7 | >16 | >16 | 1 to >16 | 7.4 | 7.4 | 85.2 | 1 | 4 | 0.25–16 |
| Meropenem | 99.3 | 0.7 | 0 | >32 | >32 | 4 to >32 | 61.7 | 9.9 | 28.4 | 8 | 32 | 0.125 to >32 |
| Meropenem/ vaborbactam | 98.5 | 1.5 | 0 | >32 | >32 | 8 to >32 | 35.8 | 22.2 | 42 | 8 | 32 | 0.25 to >32 |
| Piperacillin/ tazobactam | 98.5 | 1.5 | 0 | >64 | >64 | 32 to >64 | 29.6 | 19.8 | 50.6 | 16 | >64 | ≤8 to >64 |
| Ciprofloxacin | 99.3 | 0 | 0.7 | >16 | >16 | 1 to >16 | 56.8 | 7.4 | 35.8 | 2 | >16 | 0.06 to >16 |
| Delafloxacin | 98.5 | 0 | 1.5 | 4 | 16 | 0.25 to >32 | 56.8 | 12.3 | 30.9 | 2 | 32 | 0.125 to >32 |
| Lascufloxacin | 79.4 | 18.4 | 2.2 | 8 | 16 | 1 to >64 | 97.5 | 2.5 | 0 | 64 | >64 | 2 to >64 |
| Levofloxacin | 93.4 | 5.9 | 0.7 | 16 | >32 | ≤0.25 to >32 | 65.4 | 6.2 | 28.4 | 4 | >32 | ≤0.25 to >32 |
| Eravacycline | 80.9 | 0 | 19.1 | 1 | 2 | 0.125–8 | Intrinsic resistance | |||||
| Minocycline | 17.6 | 41.9 | 40.4 | 8 | 16 | ≤0.5–16 | Intrinsic resistance | |||||
| Omadacycline | 8.1 | 55.9 | 36 | 8 | 8 | 1–32 | Intrinsic resistance | |||||
| Tigecycline | 6.6 | 22.8 | 70.6 | 2 | 4 | 0.25–16 | Intrinsic resistance | |||||
| Amikacin | 88.2 | 0.7 | 11 | >32 | >32 | ≤4 to >32 | 2.5 | 2.5 | 95 | ≤4 | 8 | ≤4 to >32 |
| Gentamicin | 90.4 | 2.9 | 6.6 | >8 | >8 | 1 to >8 | 19.8 | 1.2 | 79 | 2 | >8 | ≤1 to >8 |
| Tobramycin | 89 | 2.2 | 8.8 | >8 | >8 | ≤1 to >8 | 19.8 | 0 | 80.2 | ≤1 | >8 | ≤1 to >8 |
| Aztreonam | Intrinsic resistance | 33 | 13.6 | 53.1 | 8 | >16 | ≤2 to >16 | |||||
| Colistin | 0.7 | 0 | 99.3 | ≤0.25 | 0.5 | ≤0.25 to >4 | 3.7 | 0 | 96 | 1 | 2 | ≤0.25 to >4 |
R, resistant; I intermediate; S, susceptible.